X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs NATCO PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA NATCO PHARMA SANOFI INDIA/
NATCO PHARMA
 
P/E (TTM) x 38.8 16.2 238.7% View Chart
P/BV x 8.4 17.5 47.8% View Chart
Dividend Yield % 1.1 0.7 165.1%  

Financials

 SANOFI INDIA   NATCO PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
NATCO PHARMA
Mar-14
SANOFI INDIA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560877 520.0%   
Low Rs4,400424 1,039.0%   
Sales per share (Unadj.) Rs1,028.5223.4 460.3%  
Earnings per share (Unadj.) Rs129.031.1 415.1%  
Cash flow per share (Unadj.) Rs186.040.3 461.8%  
Dividends per share (Unadj.) Rs68.005.00 1,360.0%  
Dividend yield (eoy) %1.50.8 197.4%  
Book value per share (Unadj.) Rs753.6219.5 343.3%  
Shares outstanding (eoy) m23.0333.07 69.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x4.42.9 149.7%   
Avg P/E ratio x34.720.9 166.0%  
P/CF ratio (eoy) x24.116.1 149.2%  
Price / Book Value ratio x5.93.0 200.7%  
Dividend payout %52.716.1 327.6%   
Avg Mkt Cap Rs m103,17421,504 479.8%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5921,128 318.5%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,6867,389 320.6%  
Other income Rs m708167 423.7%   
Total revenues Rs m24,3947,556 322.8%   
Gross profit Rs m5,2811,793 294.5%  
Depreciation Rs m1,313304 431.3%   
Interest Rs m15366 4.1%   
Profit before tax Rs m4,6611,290 361.4%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691309 547.8%   
Profit after tax Rs m2,9701,027 289.1%  
Gross profit margin %22.324.3 91.9%  
Effective tax rate %36.323.9 151.6%   
Net profit margin %12.513.9 90.2%  
BALANCE SHEET DATA
Current assets Rs m15,6733,681 425.7%   
Current liabilities Rs m6,6783,123 213.8%   
Net working cap to sales %38.07.6 502.4%  
Current ratio x2.31.2 199.1%  
Inventory Days Days7689 84.9%  
Debtors Days Days2259 38.0%  
Net fixed assets Rs m8,0987,685 105.4%   
Share capital Rs m230331 69.6%   
"Free" reserves Rs m17,0886,670 256.2%   
Net worth Rs m17,3567,259 239.1%   
Long term debt Rs m0955 0.0%   
Total assets Rs m25,40011,957 212.4%  
Interest coverage x311.74.5 6,893.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.6 150.9%   
Return on assets %11.811.7 100.8%  
Return on equity %17.114.2 120.9%  
Return on capital %26.920.7 130.0%  
Exports to sales %24.539.4 62.2%   
Imports to sales %28.05.7 490.8%   
Exports (fob) Rs m5,8012,908 199.5%   
Imports (cif) Rs m6,627421 1,573.4%   
Fx inflow Rs m7,1453,445 207.4%   
Fx outflow Rs m6,846703 974.1%   
Net fx Rs m2992,743 10.9%   
CASH FLOW
From Operations Rs m3,2261,440 224.0%  
From Investments Rs m-1,555-1,089 142.8%  
From Financial Activity Rs m-1,818-353 515.5%  
Net Cashflow Rs m-147-1 9,865.8%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 60.4 1.5 4,108.8%  
Indian inst/Mut Fund % 14.4 7.8 183.7%  
FIIs % 14.6 16.6 87.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 26.0 40.4%  
Shareholders   15,184 25,395 59.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 26, 2018 03:37 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. REDDYS LAB COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS